Author:
Huang Yue,Zou Kangni,Jiang Heng,Li Zhengyu
Abstract
AbstractThe emergence of malignant ascites (MA) indicates poor prognoses in patients with ovarian, gastrointestinal, breast, and pancreatic cancer. Interleukin-10 (IL-10) is a pleiotropic cytokine with immunoregulatory effects in tumor microenvironment. The level of IL-10 in MA varied across cancer types and patients, influencing cancer progression and outcomes. Originating from various immune and cancer cells, IL-10 contributes to complex signaling pathways in MA. Systemic IL-10 administration, although the evidence of its efficacy on MA is limited, still emerges as a promising therapeutic strategy because it can increase CD8+ T cells cytotoxicity and invigorate exhausted CD8+ tumor infiltration lymphocytes (TILs) directly. IL-10 signaling blockade also demonstrates great potential when combined with other immunotherapies in MA treatment. We reviewed the levels, origins, and functions of IL-10 in malignant ascites and overviewed the current IL-10 signaling targeting therapies, aiming to provide insights for MA treatment.
Funder
The Science and technology project of the health planning committee of Sichuan
Publisher
Springer Science and Business Media LLC
Reference124 articles.
1. Becker GGD, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42(5):589–597
2. Woopen HSJ (2009) Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res 29(8):3353–3359
3. van Baal JO, Van de Vijver KK, Nieuwland R, van Noorden CJ, van Driel WJ, Sturk A et al (2017) The histophysiology and pathophysiology of the peritoneum. Tissue Cell 49(1):95–105
4. Senger DR, de Van Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK et al (1993) Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12(3–4):303–324
5. Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A (2013) Malignant ascites: pathophysiology and treatment. Int J Clin Oncol 18(1):1–9
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献